Passenger gene co-amplifications create collateral therapeutic vulnerabilities in cancer
Bei Y, Bramé L, Kirchner M, Fritsche-Guenther R, Kunz S, Bhattacharya A, Rusu M, Gürgen D, Dubios F, Köppke J, Proba J, Wittstruck N, Sidorova O, González R, Garcia H, Brückner L, Xu R, Giurgiu M, Rodriguez-Fos E, Yu Q, Spanjaard B, Koche R, Schmitt C, Schulte J, Eggert A, Haase K, Kirwan J, Hagemann A, Mertins P, Dörr J, Henssen A. Passenger gene co-amplifications create collateral therapeutic vulnerabilities in cancer. Cancer Discovery 2024, 14: 492-507. PMID: 38197697, PMCID: PMC10911929, DOI: 10.1158/2159-8290.cd-23-1189.Peer-Reviewed Original ResearchConceptsDEAD-box helicase 1Passenger genesTherapeutic vulnerabilitiesTricarboxylic acidCRISPR-Cas9 loss-of-function screensLoss-of-function screensCell death in vitroDisruption of mTORC1Death in vitroGene co-amplificationCancer cell linesCancer genomesHelicase 1Interaction partnersCancer dependenciesCollateral vulnerabilitiesTCA activityCo-amplificationDNA amplificationMTORC1 activityCancerPharmacological disruptionCancer biologyTarget discoveryCoamplification
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply